Live Breaking News & Updates on Drug Adverse Event

Stay updated with breaking news from Drug adverse event. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice. ....

Helena Yu , Patritumab Deruxtecan , Lung Cancer , Non Small Cell Lung Cancer , Egfr Mutation , Egfr Lung Cancer , Egfr Tki , Herthena Lung01 , Her3 Dxd , Clinical Trials , Novel Therapy , World Conference On Lung Cancer , Wclc 2023 , 2023 Wclc , Efficacy Data , Safety Data , Her3 Membraneh Score , Her3 Expression , Cns Disease , Intracranial Disease , Adverse Events , Drug Adverse Event ,

The Evolving Treatment Landscape of Small Cell Lung Cancer

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm. ....

Christian Groh , Laurent Greiller , Evolving Paradigms , Evolving Treatment Landscape , Small Cell Lung , Small Cell Lung Cancer , Limited Stage Sclc , Extensive Stage Sclc , Ls Sclc , Es Sclc , Novel Therapy , Combination Therapy , Clinical Trials , Bispecific Therapy , Bispecific Antibodies , Adverse Events , Drug Adverse Event , Safety Profile , Toxicity Profile , Adc Therapy , Antibody Drug Conjugates , Egfr Mutation , Egfr Tki , Maintenance Therapy , Second Line Therapy , Second Line Treatment ,

Clinical Data With Lurbinectedin in Small Cell Lung Cancer

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy. ....

Evolving Paradigms , Data With Lurbinectedin , Small Cell Lung , Small Cell Lung Cancer , Limited Stage Sclc , Extensive Stage Sclc , Ls Sclc , Es Sclc , Second Line Therapy , Second Line Treatment , Imforte Trial , Imforte Study , Platinum Resistant , Platinum Sensitive , Maintenance Therapy , Adverse Events , Drug Adverse Event , Toxicity Profile , Safety Profile , Lagoon Trial , Lagoon Study , Novel Therapy , Combination Therapy , Clinical Trials ,

Advent of PARP Inhibitors in Metastatic CRPC

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting. ....

Treatment Approaches , Prostate Cancer , Metastatic Prostate Cancer , Castration Resistant Prostate Cancer , Parp Inhibitors , Parp Inhibition , Tissue Biopsy , Liquid Biopsy , Somatic Testing , Germline Testing , Circulating Tumor Dna , Cell Free Dna , Adverse Events , Drug Adverse Event , Talapro 2 , Arsi Therapy , Asco 2023 , Asco Annual Meeting ,

Bispecifics in Multiple Myeloma: Adverse Event Management

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma. ....

Evolving Treatment Paradigm , Multiple Myeloma , Recent Updates , Adverse Event Management , Myeloma Cancer , Relapsed Refractory Multiple Myeloma , Multiply Relapsed , Later Line Treatment , Later Line Therapy , Adverse Events , Drug Adverse Event , Cytokine Release Syndrome , Immune Effector Cell Associated Neurotoxicity Syndrome , Prophylactic Treatment , Asco 2023 , Asco Annual Meeting ,